Cervical Cancer Chemoradiation with NVX-108

Example 3

A female patient with cervical carcinoma is treated with combined radiation therapy and chemotherapy+NVX-108. Radiation dosage is 45 Gray (Gy) in 20 fractions followed by low dose-rate intracavitary application of 30 Gy to the cervical region. Chemotherapy consists of intravenous cisplatin 40 mg/m2 every week for up to 6 weekly cycles. The patient is administered a bolus IV dose of 0.2 cc/kg NVX-108 (2% w/vol DDFPe) 60 minutes prior to each dose of radiation. Follow-up shows complete response to treatment.

Free full text: Click here

US11857627B2. Fractionated radiotherapy and chemotherapy with an oxygen therapeutic (2024-01-02). NuvOx Pharma LLC [US]. Inventors: Evan C. Unger [US].

Patent 2024

Cervical Cervical carcinoma Chemotherapy Cisplatin Female Nvx 108 Oxygen Patient Radiation

Top 5 similar protocols

Variable analysis

independent variables

Radiation therapy
Chemotherapy (cisplatin 40 mg/m2 every week for up to 6 weekly cycles)
NVX-108 (0.2 cc/kg, 2% w/vol DDFPe) administered as a bolus IV dose 60 minutes prior to each dose of radiation

dependent variables

Response to treatment (complete response)

control variables

Radiation dosage (45 Gray (Gy) in 20 fractions followed by low dose-rate intracavitary application of 30 Gy to the cervical region)
Chemotherapy regimen (intravenous cisplatin 40 mg/m2 every week for up to 6 weekly cycles)

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!